Skip to main content

Table 4 Overall Survival and Value of Atezolizumab and Pembrolizumab

From: The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective

Drug and setting

OS gains in days/Grade(OS/g) & HR

C/LYG

RV

aAtezolizumab (Atezo) vs. Doc irrespective of PD-L1, vs. Doc (phase II, POPLAR) [8]

87/C HR 0.73

P = 0.040

$618,244

0.16

Atezo, low or undetectable PD-L1 vs. Doc, Phase III OAK [9, 10]

111/C HR 0.75

$475,265

0.21

Atezo, PD-L1 > 1.0% tumor cells (TC) or in tumor-infiltrating immune cells (IC) vs. Doc [10]

162/B HR 0.74

P = 0.0102

$325,644

0.30

Atezo, PD-L1, TC or IC > 5% vs. Doc, [10]

165/B

$319,974

0.31

Atezo, PD-L1 > 50% or IC > 10% vs. Doc

348/A + HR 0.41

$151,193

0.66

Pembrolizumab (Pembro) PD- L1 > 1.0% positive vs. Doc KEYNOTE − 010 [7] Subset analysis

57/D HR 0.71

P = 0.0008

$659,059

0.15

Pembro 10 mg/Kg, PD-L1 1.0% positive, KEYNOTE − 010

126/B HR 0.61

$1,490,729

0.07

Pembro 2.0 mg/Kg, >  50% positive KEYNOTE − 010

201/A HR 0.54

$186,897

0.53

  1. aThe average OS gains of Atezo in the POPLAR and OAK were 99 days at C/LYG of $551,407 and RV 0.19